FDA expands recall of blood pressure tablets after dissolution failures
The U. S. Food and Drug Administration announced on 4 November that it was recalling more than 3,700 bottles of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets after quality testing showed the tablets failed to dissolve properly, classifying the action as a Class II recall.
The recall follows a series of FDA actions that began on 26 October, when the agency classified a recall of over 3,700 bottles of the same generic blood-pressure medication as Class II because of dissolution failures. Earlier that day, the FDA also issued a Class II recall of two lots of the three-component tablets, and a separate Class III recall of more than 21,000 bottles of telmisartan and amlodipine tablets over potency concerns.